Therapeutic lymphangiogenesis ameliorates established acute lung allograft rejection
Ye Cui(Capital Medical University), Souheil El‐Chemaly(AVEO Oncology (United States)), Robert F. Padera(Brigham and Women's Hospital), Gautam George(Harvard University), Kaifeng Liu(Yangzhou University), Hilary J. Goldberg(Harvard University), Iván O. Rosas(Brigham and Women's Hospital), Gary Visner(Boston Children's Hospital), Mark A. Perrella(Brigham and Women's Hospital), Hao Wang(Johns Hopkins University), Demet Toprak(Boston Children's Hospital), Maria E. Monzon-Medina, Rosanna Forteza(University of Miami), Emmanuel D’Agostino(Harvard University), Elie Abdelnour(Brigham and Women's Hospital)
Cited by 99
Related Papers
Persistence and Evolution of SARS-CoV-2 in an Immunocompromised Host
|New England Journal of Medicine|2020|1.4k
Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers
|Nature Medicine|2008|1.3k
Efficacy and Safety of Sirolimus in Lymphangioleiomyomatosis
|New England Journal of Medicine|2011|1.1k
Promotion of vascular smooth muscle cell growth by homocysteine: a link to atherosclerosis.
|Proceedings of the National Academy of Sciences|1994|806
Tumor necrosis factor downregulates an endothelial nitric oxide synthase mRNA by shortening its half-life.
|Circulation Research|1993|776